Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Nuclear Medicine Communications
|
December 1, 2017
Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer
Brenda E Pratt, Cecilia Hindorf, Sarah J Chittenden, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 27, 2019
Compartmental Model for <sup>223</sup>Ra-Dichloride in Patients With Metastatic Bone Disease From Castration-Resistant Prostate Cancer
Jan Taprogge, Iain Murray, Jonathan Gear, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 29, 2009
Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma
Susan E Buckley, Sarah J Chittenden, Frank H Saran, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 18, 2009
A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer
Glenn D Flux, Masud Haq, Sarah J Chittenden, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 18, 2015
A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
Sarah J Chittenden, Cecilia Hindorf, Christopher C Parker, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
April 2, 2003
Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG
Glenn D Flux, Matt J Guy, Periklis Papavasileiou, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 15, 2017
The potential of <sup>223</sup>Ra and <sup>18</sup>F-fluoride imaging to predict bone lesion response to treatment with <sup>223</sup>Ra-dichloride in castration-resistant prostate cancer
Iain Murray, Sarah J Chittenden, Ana M Denis-Bacelar, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 23, 2003
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer
Francesca M Buffa, Glenn D Flux, Matt J Guy, et al.
The British Journal of Radiology
|
January 3, 2018
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy
Ana M Denis-Bacelar, Sarah J Chittenden, V Ralph McCready, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
June 30, 2007
Optimization of equipment and methodology for whole body activity retention measurements in children undergoing targeted radionuclide therapy
Sarah J Chittenden, Brenda E Pratt, Kay Pomeroy, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Nuclear Medicine Communications
|
December 1, 2017
Excretion and whole-body retention of radium-223 dichloride administered for the treatment of bone metastases from castration resistant prostate cancer
Brenda E Pratt, Cecilia Hindorf, Sarah J Chittenden, et al.
International Journal of Radiation Oncology, Biology, Physics
|
July 27, 2019
Compartmental Model for <sup>223</sup>Ra-Dichloride in Patients With Metastatic Bone Disease From Castration-Resistant Prostate Cancer
Jan Taprogge, Iain Murray, Jonathan Gear, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 29, 2009
Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma
Susan E Buckley, Sarah J Chittenden, Frank H Saran, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
September 18, 2009
A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer
Glenn D Flux, Masud Haq, Sarah J Chittenden, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 18, 2015
A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases
Sarah J Chittenden, Cecilia Hindorf, Christopher C Parker, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
April 2, 2003
Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG
Glenn D Flux, Matt J Guy, Periklis Papavasileiou, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 15, 2017
The potential of <sup>223</sup>Ra and <sup>18</sup>F-fluoride imaging to predict bone lesion response to treatment with <sup>223</sup>Ra-dichloride in castration-resistant prostate cancer
Iain Murray, Sarah J Chittenden, Ana M Denis-Bacelar, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 23, 2003
A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer
Francesca M Buffa, Glenn D Flux, Matt J Guy, et al.
The British Journal of Radiology
|
January 3, 2018
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy
Ana M Denis-Bacelar, Sarah J Chittenden, V Ralph McCready, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
June 30, 2007
Optimization of equipment and methodology for whole body activity retention measurements in children undergoing targeted radionuclide therapy
Sarah J Chittenden, Brenda E Pratt, Kay Pomeroy, et al.
Page
of 2